Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F–driven mouse model of MPNs

Blood - Tập 123 - Trang 3943-3950 - 2014
Adrian Duek1, Pontus Lundberg1, Takafumi Shimizu1, Jean Grisouard1, Axel Karow1, Lucia Kubovcakova1, Hui Hao-Shen1, Stephan Dirnhofer2, Radek C. Skoda1
1Department of Biomedicine, Experimental Hematology, and Basel, Switzerland
2Institute of Pathology, University Hospital Basel, Basel, Switzerland

Tóm tắt

Key Points Stat1 deletion in the presence of JAK2-V617F alters phenotypic manifestations by reducing megakaryopoiesis and favoring erythropoiesis. IFNγ is elevated in serum of mice with thrombocytosis and in patients with essential thrombocythemia and may drive Stat1 activation.

Tài liệu tham khảo

Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546 Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders., Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9 Levine, 2008, Myeloproliferative disorders., Blood, 112, 2190, 10.1182/blood-2008-03-077966 Tefferi, 2009, Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics., Nat Rev Clin Oncol, 6, 627, 10.1038/nrclinonc.2009.149 Van Etten, 2011, The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues., Haematologica, 96, 590, 10.3324/haematol.2010.035675 Li, 2011, Mouse models of myeloproliferative neoplasms: JAK of all grades., Dis Model Mech, 4, 311, 10.1242/dmm.006817 Scott, 2006, Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia., Blood, 108, 2435, 10.1182/blood-2006-04-018259 Tiedt, 2008, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice., Blood, 111, 3931, 10.1182/blood-2007-08-107748 Chen, 2010, Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling., Cancer Cell, 18, 524, 10.1016/j.ccr.2010.10.013 Huang, 2007, STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice., J Clin Invest, 117, 3890, 10.1172/JCI33010 Penta, 1995, Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells., J Biol Chem, 270, 31282, 10.1074/jbc.270.52.31282 Halupa, 2005, A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution., Blood, 105, 552, 10.1182/blood-2003-09-3237 Durbin, 1996, Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease., Cell, 84, 443, 10.1016/S0092-8674(00)81289-1 Göthert, 2005, In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis., Blood, 105, 2724, 10.1182/blood-2004-08-3037 de Boer, 2003, Transgenic mice with hematopoietic and lymphoid specific expression of Cre., Eur J Immunol, 33, 314, 10.1002/immu.200310005 Pronk, 2007, Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy., Cell Stem Cell, 1, 428, 10.1016/j.stem.2007.07.005 Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms., Blood, 100, 2292, 10.1182/blood-2002-04-1199 Tefferi, 2007, Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel., Blood, 110, 1092, 10.1182/blood-2007-04-083501 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes., Blood, 114, 937, 10.1182/blood-2009-03-209262 Godfrey, 2012, JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone., Blood, 120, 2704, 10.1182/blood-2012-05-431791 Menon, 2006, Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis., J Clin Invest, 116, 683, 10.1172/JCI25227 Porpiglia, 2012, Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities., PLoS Biol, 10, e1001383, 10.1371/journal.pbio.1001383 Yan, 2012, Critical requirement for Stat5 in a mouse model of polycythemia vera., Blood, 119, 3539, 10.1182/blood-2011-03-345215 Walz, 2012, Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice., Blood, 119, 3550, 10.1182/blood-2011-12-397554 Takayama, 2010, Genetic analysis of hierarchical regulation for Gata1 and NF-E2 p45 gene expression in megakaryopoiesis., Mol Cell Biol, 30, 2668, 10.1128/MCB.01304-09 Vyas, 1999, Consequences of GATA-1 deficiency in megakaryocytes and platelets., Blood, 93, 2867, 10.1182/blood.V93.9.2867.409k24_2867_2875 Tsuji-Takayama, 1996, Interferon-gamma enhances megakaryocyte colony-stimulating activity in murine bone marrow cells., J Interferon Cytokine Res Villeval, 1997, High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice., Blood, 90, 4369, 10.1182/blood.V90.11.4369